Targets › PGLYRP4
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Nov 2026.
Pattern receptor that binds to murein peptidoglycans (PGN) of Gram-positive bacteria. Has bactericidal activity towards Gram-positive bacteria. (UniProt, Q96LB8)
Open in Phaseline: the race on PGLYRP4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Aura Biosciences | AU-011 anti-PGLYRP4 antibody-drug conjugate | PGLYRP4 | Phase 2 | Eye Cancer; Non-muscle-invasive Bladder Cancer | Nov 2026 |
Eye Cancer (1) Non-muscle-invasive Bladder Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.